Clinical trials: Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events.
- Conditions
- Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bloodstream Infection
- Trial name
- Clopido-SNAP 2 (NCT06650488)
- Testing
- Clopidogrel, Aspirin
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- Todd C. Lee MD MPH FIDSA
Staphylococcal Bacteraemia
DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia
This is a Phase 2b clinical study, multicenter, randomized, open-label, assessor-blinded, superiority study. The study will compare dalbavancin to standard of care antibiotic therapy for the completion of therapy in patients with…
- Trial name
- NCT04775953
- Testing
- Cefazolin, Dalbavancin, Daptomycin
- Where
- 24 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Skin Diseases, Infectious
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
The aim of this study is to see the efficacy and safety of BAY1192631 in Japanese patients with methicillin-resistant staphylococcus aureus (MRSA) (skin and soft tissue infections (SSTI) and SSTI-related bacteremia).
- Trial name
- NCT01967225
- Testing
- Tedizolid Phosphate (Sivextro, BAY1192631), Linezolid
- Where
- 46 sites in Japan
- Volunteers
- 125 people
- Sponsor
- Bayer
Staphylococcus Aureus Bacteremia
Identification and Validation of Clinical Phenotypes in Staphylococcus Aureus Bacteremia and Their Association With Mortality and Development of Complicated Bacteremia
The goal of this observational study is to determine retrospectively whether different patient clinical phenotypes (adults and children) develop Staphylococcus aureus bacteremia.The main questions it aims to answer qre: 1.
- Trial name
- FEN-AUREUS (NCT06574399)
- Where
- Spain
- Volunteers
- 1,000 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Staphylococcus Aureus Bacteremia
Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia
Staphylococcus aureus bacteraemia is a frequent and life-threatening infection, despite current standard antibiotic monotherapy.
- Trial name
- BACSAFO (NCT06695832)
- Where
- 6 sites in Australia, Canada and 1 more
- Volunteers
- 369 people
- Sponsor
- Hospital Universitari de Bellvitge
Staph Aureus Bacteremia
Optimizing the Management of Staphylococcus Aureus Bacteremia (OPTIMUS-SAB)
Staphylococcus aureus bacteremia (SAB) is associated with high morbidity and mortality rates with an incidence disproportionately higher in vulnerable populations.
- Trial name
- NCT06338176
- Testing
- OPTIMUS-SAB clinical care pathway
- Where
- 101 sites in Canada
- Volunteers
- 2,542 people
- Sponsor
- University of Alberta
Staphylococcal Infections, Meningitis
Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections
Methicillin-resistant Staphylococcus aureus (SA) is a major pathogen causing mainly health-care associated infections and, lately, also community acquired infections. Few treatment choices exist to treat these infections.
- Conditions
- Staphylococcal Infections, Meningitis, Sepsis, Pneumonia
- Trial name
- NCT00427076
- Testing
- Cotrimoxazole, Vancomycin
- Where
- 2 sites in Israel
- Volunteers
- 252 people
- Sponsor
- Rabin Medical Center
Bacteremia
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
Patients with MRSaB have high therapeutic failure rates and mortality rates. Recent studies have shown that an elevated IL-10 level is an independent risk factor of mortality.
- Trial name
- NCT02660346
- Testing
- Daptomycin, Vancomycin, Ceftaroline
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sharp HealthCare
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking oral anticoagulant medications (apixaban, edoxaban, or rivaroxaban) for an approved indication (stroke…
- Conditions
- Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Bloodstream Infection
- Trial name
- DABI-SNAP (NCT06650501)
- Testing
- Dabigatran, Apixaban, edoxaban
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Staphylococcus Aureus, Bacteremia
Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)
This study will assess the efficacy of a single dose of V710 vaccine to prevent serious Staphylococcus aureus infections following elective cardiothoracic surgery.
- Conditions
- Staphylococcus Aureus, Bacteremia, Mediastinitis
- Trial name
- NCT00518687
- Testing
- V710
- Volunteers
- 8,031 people
- Sponsor
- Merck Sharp & Dohme LLC
Staphylococcus Aureus Bacteremia, Anti-Bacterial Agents
Phase IIa Clinical Study of N-Rephasin® SAL200
This study is performed to evaluate safety and to explore the efficacy of a single intravenous dose of N-Rephasin® SAL200 (3 mg/kg) in addition to the conventional standard treatment, for persistent Staphylococcus aureus…
- Trial name
- NCT03089697
- Testing
- N-Rephasin® SAL200
- Where
- 2 sites in South Korea
- Volunteers
- 25 people
- Sponsor
- Intron Biotechnology, Inc.
Staphylococcus Aureus Endocarditis, Prosthetic Valve Endocarditis
Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus
This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S.
- Trial name
- RIFA-SNAP (NCT07253688)
- Testing
- Rifampin, No rifampin
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Todd C. Lee MD MPH FIDSA
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
The purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of CF-301 in addition to background standard of care (SOC) antibacterial therapy for the treatment of Staphylococcus aureus (S.
- Trial name
- NCT03163446
- Testing
- CF-301
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 121 people
- Sponsor
- ContraFect
Staphylococcus Aureus Bacteremia
Evaluating Simplified Layered Consent for Clinical Trials
The goal of this clinical trial (the SIMPLY-SNAP trial) is to compare a simplified layered consent form to a full-length consent form for use during the informed consent process for a larger clinical trial of treatment of…
- Trial name
- SIMPLY-SNAP (NCT06168474)
- Testing
- Simplified layered consent form, Full-length consent form
- Where
- 6 sites in Canada
- Volunteers
- 347 people
- Sponsor
- Sunnybrook Health Sciences Centre
Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology
Staphylococcus aureus bacteremia: impact of an intervention program in improving the clinical management and review of the clinical and molecular epidemiology.
- Trial name
- NCT01971762
- Testing
- Follow recommendations based on scientific evidence to S. aureus bacteremia management, Not to follow recommendations based on scientific evidence to S. aureus bacteremia management
- Where
- 16 sites in Spain
- Volunteers
- 600 people
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
Bacteremia, Staphylococcal Infection
MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial
In-vitro identification of S. aureus, methicillin-sensitive S. aureus (MSSA), and methicillin-resistant S. aureus (MRSA) from positive blood cultures by MicroPhage's bacteriophage-based diagnostic platform.
- Conditions
- Bacteremia, Staphylococcal Infection, Sepsis, Infection
- Trial name
- NCT00814151
- Testing
- MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)
- Where
- 3 sites in United States
- Volunteers
- 712 people
- Sponsor
- MicroPhage, Inc.
Nosocomial Infection, Healthcare-associated Infection
Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia
Hypothesis: The use of daptomycin to treat nosocomial or healthcare-associated bacteremia due to methicillin-resistant S. aureus (MRSA) would increase the proportion of patients whose blood cultures are sterilized after 72 hours…
- Trial name
- DAVASAB (NCT01515020)
- Testing
- vancomycin monotherapy, daptomycin monotherapy
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Staphylococcus Aureus Bacteremia
Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia
Introduction: Staphylococcus aureus bacteremia (SAB) plays an important role in long-course antibiotic therapy. Current international guidelines recommend fourteen days of intravenous antibiotic treatment for SAB in order to…
- Trial name
- SAB7 (NCT03514446)
- Testing
- Antibiotic therapy duration for 7 days
- Where
- Denmark
- Volunteers
- 284 people
- Sponsor
- Thomas Benfield
Staphylococcus Aureus Bacteremia
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).
- Trial name
- NCT03138733
- Testing
- Ceftobiprole medocaril, Daptomycin
- Where
- 60 sites in United States, Argentina and 15 more
- Volunteers
- 390 people
- Sponsor
- Basilea Pharmaceutica
Bacteremia Due to Staphylococcus Aureus
Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia
The aim of this study is to compare the efficacy of daptomycin treatment versus vancomycin treatment in the treatment of methicillin resistant staphylococcus aureus (MRSA) bloodstream infections (BSI) due to isolates with high…
- Trial name
- NCT01975662
- Testing
- Daptomycin, Vancomycin
- Where
- Singapore
- Volunteers
- 14 people
- Sponsor
- Singapore General Hospital